• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biogen says U.S. FTC, SEC probing Alzheimer's disease drug

Emily

Editor, Senior Moderator
They better clean house at the FDA quickly. Dr. Tom Friedan said on Twitter that the Defense Department is considering taking over the FDA. (Correction: I think that was actually the CDC discussed in the tweet, not the FDA - E)

https://finance.yahoo.com/news/bioge...113535546.html
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Fri, February 4, 2022, 5:35 AM
(Reuters) - The U.S. Federal Trade Commission and the U.S. Securities and Exchange Commission have asked Biogen Inc to provide information on the approval and marketing of its new Alzheimer's disease treatment, Aduhelm, the drugmaker disclosed in a filing.

Biogen in its annual report on Thursday said it received a civil investigative demand, similar to a subpoena, from the FTC. The FTC is tasked with oversight of industry competition and consumer protection.

The SEC regulates securities markets and works to protect investors.

The U.S. Food and Drug Administration in June approved Biogen's Aduhelm - the first treatment for Alzheimer's in decades - despite one of its two large-scale clinical trials failing to show a benefit to patients. A panel of its expert advisers voted against the drug, and some panel members resigned.

In July, the FDA asked the Office of the Inspector General for the Department of Health and Human Services to open an investigation into interactions with Biogen related to the approval of the drug.

U.S. lawmakers have also launched an investigation into the drug...
 
Last edited:
Back
Top